Dr. Kriachok on Ukrainian patients navigating both war, blood cancer care
At the onset of the war in Ukraine, many cancer patients faced immense challenges, with some seeking safety abroad or relocating to more
At the onset of the war in Ukraine, many cancer patients faced immense challenges, with some seeking safety abroad or relocating to more
In this engaging discussion, Dr. Nitin Jain interviews Dr. Hagop Kantarjian, a global pioneer in leukemia care, about groundbreaking advancements in leukemia and
The US Food and Drug Administration (FDA) has approved revumenib for relapsed or refractory acute leukemia with KMT2A translocation in adult and pediatric patients
On August 28, 2023, the US Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) as a first-line treatment for anemia in adult patients
Epcoritamab monotherapy showed a “manageable safety profile” and “clinically meaningful activity” in patients with relapsed or refractory follicular lymphoma who had at least
In this video interview from the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO), Bijal Shah, MD, of the Moffitt Cancer
Patients with newly diagnosed chronic myeloid leukemia (CML) showed better response rates and higher safety when treated with asciminib compared with standard tyrosine
The Society of Hematologic Oncology (SOHO) will be holding a joint session with two Spain-based hematology societies: la Sociedad Española de Hematología y
Luspatercept is more effective than epoetin alfa in achieving transfusion independencin anemia patients with lower-risk myelodysplastic syndromes (MDS), according to a primary analysis
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who relapsed after frontline ponatinib-based therapies had a high response rate to salvage treatments,